Legato Capital Management LLC Acquires Shares of 63,625 Beta Bionics, Inc. $BBNX

Legato Capital Management LLC acquired a new stake in shares of Beta Bionics, Inc. (NASDAQ:BBNX) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 63,625 shares of the company’s stock, valued at approximately $1,264,000.

A number of other institutional investors also recently modified their holdings of BBNX. GPS Wealth Strategies Group LLC raised its position in Beta Bionics by 45.0% during the 3rd quarter. GPS Wealth Strategies Group LLC now owns 1,450 shares of the company’s stock valued at $29,000 after purchasing an additional 450 shares during the last quarter. EverSource Wealth Advisors LLC grew its position in shares of Beta Bionics by 203.6% in the 3rd quarter. EverSource Wealth Advisors LLC now owns 2,377 shares of the company’s stock worth $47,000 after buying an additional 1,594 shares during the last quarter. Strs Ohio purchased a new position in shares of Beta Bionics during the first quarter valued at approximately $29,000. Ameritas Investment Partners Inc. raised its holdings in shares of Beta Bionics by 139.1% during the third quarter. Ameritas Investment Partners Inc. now owns 3,202 shares of the company’s stock valued at $64,000 after acquiring an additional 1,863 shares in the last quarter. Finally, Legal & General Group Plc lifted its stake in Beta Bionics by 197.4% in the second quarter. Legal & General Group Plc now owns 3,976 shares of the company’s stock worth $58,000 after acquiring an additional 2,639 shares during the period.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on BBNX. Robert W. Baird reduced their price objective on shares of Beta Bionics from $28.00 to $14.00 and set a “neutral” rating on the stock in a research report on Wednesday, February 18th. The Goldman Sachs Group reiterated a “buy” rating and set a $25.00 price target on shares of Beta Bionics in a research report on Thursday, January 15th. Wall Street Zen lowered shares of Beta Bionics from a “hold” rating to a “sell” rating in a report on Saturday, January 10th. Truist Financial reduced their target price on Beta Bionics from $37.00 to $25.00 and set a “buy” rating on the stock in a report on Monday, February 2nd. Finally, TD Cowen assumed coverage on Beta Bionics in a research report on Monday, January 26th. They issued a “hold” rating and a $17.00 target price for the company. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Beta Bionics presently has an average rating of “Moderate Buy” and an average price target of $23.20.

Beta Bionics Stock Down 7.6%

NASDAQ:BBNX opened at $11.57 on Wednesday. Beta Bionics, Inc. has a 52 week low of $8.89 and a 52 week high of $32.71. The stock has a market cap of $513.48 million, a price-to-earnings ratio of -5.93 and a beta of 5.60. The company’s 50 day moving average price is $18.74 and its 200-day moving average price is $22.43.

Beta Bionics (NASDAQ:BBNX) last issued its earnings results on Tuesday, February 17th. The company reported ($0.30) EPS for the quarter, beating the consensus estimate of ($0.42) by $0.12. Beta Bionics had a negative return on equity of 20.29% and a negative net margin of 73.02%.The business had revenue of $32.12 million for the quarter.

Beta Bionics News Summary

Here are the key news stories impacting Beta Bionics this week:

• Positive Sentiment: Quarterly results showed an EPS beat (reported ($0.30) vs. consensus ($0.42)) and $32.1M revenue, which signals operational progress even though the company remains unprofitable. MarketBeat BBNX overview
• Neutral Sentiment: Short‑interest reporting appears inconsistent/erroneous in recent filings (values shown as 0 shares/NaN), so short‑interest data is unreliable right now and not a confirmed driver of today’s move.
• Negative Sentiment: Multiple executives sold stock on Mar 2–3 at an average price of $12.36 — a visible wave of insider selling that markets often interpret as a negative signal about near‑term insider conviction. Coverage summary: several top managers reduced positions in small single‑thousand share lots. TipRanks: Insider sales story
• Negative Sentiment: Documented Form 4 sales (selected filings): CFO Stephen Feider sold 1,428 shares (~$17.65K) — SEC filing: Feider Form 4; Mike Mensinger sold 1,064 shares — SEC filing: Mensinger Form 4; Steven Jon Russell sold 1,026 shares — SEC filing: Russell Form 4; Mark Hopman sold 834 shares — SEC filing: Hopman Form 4
• Negative Sentiment: Shareholder litigation outreach: Faruqi & Faruqi announced an investigation into potential claims on behalf of BBNX investors — this can increase legal risk and create additional selling pressure. GlobeNewswire: Faruqi & Faruqi notice

Insider Buying and Selling

In other news, insider Mike Mensinger sold 2,200 shares of the business’s stock in a transaction that occurred on Tuesday, January 6th. The shares were sold at an average price of $30.10, for a total transaction of $66,220.00. Following the completion of the transaction, the insider directly owned 80,752 shares of the company’s stock, valued at $2,430,635.20. The trade was a 2.65% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Stephen Feider sold 20,000 shares of the firm’s stock in a transaction that occurred on Friday, January 2nd. The stock was sold at an average price of $29.53, for a total transaction of $590,600.00. Following the completion of the sale, the chief financial officer owned 42,614 shares in the company, valued at $1,258,391.42. This represents a 31.94% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 34,352 shares of company stock valued at $941,569 over the last quarter.

About Beta Bionics

Beta Bionics, a clinical-stage medical device company headquartered in Boston, Massachusetts, is focused on revolutionizing the management of type 1 diabetes through automated insulin delivery solutions. The company’s flagship product, the iLet Bionic Pancreas system, is designed to simplify glycemic control by automatically adjusting insulin dosing in response to continuous glucose monitoring data. By integrating advanced algorithmic control with wearable infusion pumps, the iLet aims to reduce the daily burden of diabetes management and improve clinical outcomes for patients.

At the core of Beta Bionics’ offering is its proprietary bionic pancreas software, which can operate in both insulin-only and dual‐hormone modes.